Edwards Backs Limits on Heart Valve to Assure U.S. Coverage

Edwards Lifesciences Corp. accepted restrictions on its Sapien heart valve that may cut U.S. sales $100 million in 2015 in exchange for guarantees Medicare will pay for its use in patients too sick for chest-opening surgery.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.